Glenmark launches NCOVD-19 medicine
News
Glenmark has received approval to manufacture and market Favipiravir in India treatment of patients with mild to moderate COVID-19.Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases .Price at ₹103 per tablet, 200 mg tablet at MRP of ₹3,500 for 34 tablets.
The dose of Favipiraviris 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14. It is a prescription-based medicine.
Comments
Post a Comment
Thanks for comments